Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 5/20 | 0.91 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.91 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.91 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.91 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.91 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.91 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.91 |
| ▸ | LMNA | P02545 | 4/20 | 0.91 |
| ▸ | MAPT | P10636 | 4/20 | 0.91 |
| ▸ | HPGD | P15428 | 4/20 | 0.91 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.91 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.91 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.91 |
| ▸ | TTR | P02766 | 3/20 | 0.91 |
| ▸ | TP53 | P04637 | 3/20 | 0.91 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.91 |
| ▸ | MEN1 | O00255 | 3/20 | 0.91 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.91 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.91 |
| ▸ | THPO | P40225 | 3/20 | 0.91 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15026144 | 1.00 | LCK (0.91) | LCKCYP3A4CYP2C9HIF1AHSD17B10 | |
| Piceatannol SCHEMBL29929133 | 0.95 | LCK (1.00) | LCKCYP3A4CYP2C9HIF1AHSD17B10 | |
| Piceatannol SCHEMBL43541 | 0.95 | LCK (1.00) | LCKCYP3A4CYP2C9HIF1AHSD17B10 | |
| Piceatannol SCHEMBL29754702 | 0.95 | LCK (1.00) | LCKCYP3A4CYP2C9HIF1AHSD17B10 | |
| Piceatannol SCHEMBL505561 | 0.95 | LCK (1.00) | LCKCYP3A4CYP2C9HIF1AHSD17B10 | |
| Piceatannol SCHEMBL29501290 | 0.95 | LCK (1.00) | LCKCYP3A4CYP2C9HIF1AHSD17B10 | |
| Piceatannol SCHEMBL19953785 | 0.95 | LCK (1.00) | LCKCYP3A4CYP2C9HIF1AHSD17B10 | |
| SCHEMBL13409618 | 0.89 | LCK (0.72) | LCKCYP3A4CYP2C9HIF1AHSD17B10 | |
| SCHEMBL31706727 | 0.88 | LCK (1.00) | LCKCYP3A4CYP2C9HIF1AHSD17B10 | |
| SCHEMBL30631591 | 0.88 | LCK (1.00) | LCKCYP3A4CYP2C9HIF1AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2749552-B1 | Curcumin-resveratrol hybrids | CODMAN & SHURTLEFF (US) | 2015-11-18 | — | — | EP | claimed |
| EP-2749552-A1 | Curcumin-resveratrol hybrids | Codman & Shurtleff, Inc. (US) | 2014-07-02 | — | — | EP | claimed |
| EP-2382176-A1 | USE OF NITROGEN-CONTAINING CURCUMIN ANALOGS FOR THE TREATMENT ALZHEIMER'S DISEASE | Codman & Shurtleff, Inc. (US) | 2011-11-02 | — | — | EP | claimed |
| US-7745670-B2 | Curcumin-Resveratrol hybrid molecule | CODMAN & SHURTLEFF, INC. (US) | 2010-06-29 | — | — | US | claimed |
| US-20090326275-A1 | USE OF NITROGEN-CONTAINING CURCUMIN ANALOGS FOR THE TREATMENT OF ALZHEIMERS DISEASE | DEPUY SPINE, LLC | 2009-12-31 | — | — | US | claimed |
| EP-2749552-B1 | Curcumin-resveratrol hybrids | CODMAN & SHURTLEFF (US) | 2015-11-18 | — | — | EP | disclosed |
| US-8609652-B2 | Method of administering a methylene blue-curcumin analog for the treatment of alzheimer's disease | DePuy Synthes Products, LLC (US) | 2013-12-17 | — | — | US | disclosed |
| US-8350093-B2 | Methylated curcumin-resveratrol hybrid molecules for treating cancer | CODMAN & SHURTLEFF, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| EP-2382176-A1 | USE OF NITROGEN-CONTAINING CURCUMIN ANALOGS FOR THE TREATMENT ALZHEIMER'S DISEASE | Codman & Shurtleff, Inc. (US) | 2011-11-02 | — | — | EP | disclosed |
| EP-2359820-A1 | Shunt delivery of curcumin for the treatment Alzneimer | Codman & Shurtleff, Inc. (US) | 2011-08-24 | — | — | EP | disclosed |
| US-20110130392-A1 | Method of Administering a Methylene Blue - Curcumin Analog for the Treatment of Alzheimer's Disease | DEPUY SPINE, LLC | 2011-06-02 | — | — | US | disclosed |
| US-7906643-B2 | Methylene blue-curcumin analog for the treatment of Alzheimer's Disease | CODMAN & SHURTLEFF, INC. (US) | 2011-03-15 | — | — | US | disclosed |
| US-20100292512-A1 | Methylated Curcumin-Resveratrol Hybrid Molecules for Treating Cancer | DEPUY SPINE, LLC | 2010-11-18 | — | — | US | disclosed |
| US-20100286585-A1 | Shunt Delivery of Curcumin | CODMAN & SHURTLEFF, INC. (US) | 2010-11-11 | — | — | US | disclosed |
| US-20100190978-A1 | METHYLENE BLUE - CURCUMIN ANALOG FOR THE TREATMENT OF ALZHEIMER'S DISEASE | CODMAN & SHURTLEFF, INC. | 2010-07-29 | — | — | US | disclosed |
| US-7745670-B2 | Curcumin-Resveratrol hybrid molecule | CODMAN & SHURTLEFF, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-7723515-B1 | Methylene blue—curcumin analog for the treatment of alzheimer's disease | CODMAN & SHURTLEFF, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-20090326275-A1 | USE OF NITROGEN-CONTAINING CURCUMIN ANALOGS FOR THE TREATMENT OF ALZHEIMERS DISEASE | DEPUY SPINE, LLC | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292512-A1 | Methylated Curcumin-Resveratrol Hybrid Molecules for Treating Cancer | DNMT1, MECP2, BMI1 | LCK 4376/4885CYP3A4 2301/4885CYP2C9 3451/4885 |
| US-20100190978-A1 | METHYLENE BLUE - CURCUMIN ANALOG FOR THE TREATMENT OF ALZHEIMER'S DISEASE | APP, PSEN2, MAPT | LCK 4450/4885CYP3A4 1823/4885CYP2C9 1998/4885 |
| US-20090326275-A1 | USE OF NITROGEN-CONTAINING CURCUMIN ANALOGS FOR THE TREATMENT OF ALZHEIMERS DISEASE | SLC1A3, SLC1A1, SLC1A2 | LCK 3898/4885CYP3A4 2942/4885CYP2C9 2990/4885 |
| US-20110130392-A1 | Method of Administering a Methylene Blue - Curcumin Analog for the Treatment of Alzheimer's Disease | APP, PSEN2, MAPT | LCK 4610/4885CYP3A4 1474/4885CYP2C9 1204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.